Abstract: Over the past decade, interest has been generated in the study of endothelial progenitor cells (EPCs). EPCs have been studied for their role in endogenous maintenance and for their therapeutic potential in vascular regenerative medicine. Despite their obvious potential in clinical practice, there still remain many controversies regarding how EPCs actually enhance endothelial repair and neovascularization. In addition, because of the limited expansion ability of EPCs, expansion of sufficient EPC populations for therapeutic angiogenesis remains a major task. On the other hand, embryonic stem (ES) cells have an extended self-renewal activity and can be expanded without limit, thus ES-cell-derived endothelial cells could be feasible as a novel cell source for therapeutic angiogenesis. In this review, we discuss recent experimental and clinical findings of EPCs and human ES-cell-derived endothelial cells for the treatment of ischemic cardiovascular diseases.
Introduction
Neovascularization represents the formation of new blood vessels, either from the preexisting vascular network (angiogenesis) or through a de novo process from circulating primitive endothelial precursors (vasculogenesis) [Asahara et al. 1999a; Takahashi et al. 1999; Shi et al. 1998; Folkman, 1995] . Many researchers have reported the identification and isolation of endothelial progenitor cells (EPCs) participating in vasculogenesis [Asahara et al. 1997] . EPCs were originally identified in the peripheral blood of bone marrow (BM) origin [Asahara et al. 1997] , and later studies indicated that cord blood is a rich source of EPCs [Murohara et al. 2000] . These EPCs are now being studied for their role in the endogenous maintenance and repair of damaged endothelium, as well as for their regenerative potential. In particular, cell therapies using EPCs have proven beneficial in patients with coronary artery disease [Assmus et al. 2002] . The Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) trial showed that intracoronary infusion of EPCs was safe and feasible in patients with AMI who successfully revascularized via stent implantation [Schachinger et al. 2004; Assmus et al. 2002] . However, in spite of the angiogenic potential of EPCs for treatment of ischemic diseases, these cell sources have limitations for clinical application. To isolate EPCs in sufficient numbers requires a large amount of blood or BM [Kalka et al. 2000] This may cause complications in some patients with severe cardiovascular disease including myocardial infarction.
Recently, embryonic stem (ES) cells have been highlighted as a promising cell source for therapeutic angiogenesis. ES cells are known to exhibit extensive regeneration potential and functional multilineage differentiation capacity, and they are ideal resources for regenerative medicine, which requires large numbers of transplant cells including endothelial cells (ECs) [Yamashita et al. 2000] . After the in vitro induction of differentiation in mouse and human ES cells, ECs can be obtained from vascular endothelial growth factor receptor (VEGFR)-2 positive cell fractions [Sone et al. 2007 [Sone et al. , 2003 Yamashita et al. 2000] . ES-cell-derived ECs express endothelial-specific markers and have been found to form capillary structures in vitro and in vivo [Yamahara et al. 2008; Sone et al. 2007; Yurugi-Kobayashi et al. 2003 ]. In addition, previous studies reported that transplantation of human ES-cellderived ECs accelerated vascular regeneration in mouse hindlimb ischemia [Yamahara et al. 2008; Cho et al. 2007] . Thus, ES cells could be a promising source of ECs for the treatment of ischemia. In this review, recent experimental and clinical findings of these cell sources will be discussed along with our recent studies using mouse and human ES cells.
Definition of EPCs
Circulating EPCs were first described by Asahara et al. [1997] who showed that human peripheral blood cells enriched in both CD34 þ and VEGFR-2 þ cells could differentiate into mature ECs and form new vessels in vivo. Both CD34 and VEGFR-2 are expressed on primary hemangioblast islets in the yolk sac mesoderm during early embryonic vasculogenesis [Pelosi et al. 2002] . Therefore, CD34 þ VEGFR-2 þ can be considered immature cells and represent putative EPCs. However, CD34 is expressed on hematopoietic stem cells and on the activated endothelium of certain microvasculature, but not on large vessels [Fina et al. 1990] . VEGFR-2 is also expressed on hematopoietic stem cells and mature endothelial cells [Ziegler et al. 1999] . In addition, recent evidence suggests that since different subsets of BM or circulating cells can differentiate into endothelial-like cells, the original definition of EPCs as CD34 þ /VEGFR-2 þ might not represent all EC progenitors. The various markers used so far to identify EPCs indicate the uncertainty of the precise angiogenic phenotype of EPCs. Some studies have identified CD133 as an additional marker which is never expressed on mature endothelial cells. However this marker is expressed on more immature cells than CD34 is and so occur-
þ cells in circulation. Despite these limitations, several studies chose CD34/VEGFR-2 or CD34/CD133 combinations to count circulating EPCs in several clinical conditions [Ghani et al. 2005; Heiss et al. 2005; George et al. 2003; Heeschen et al. 2003; Cho et al. 2003; Gill et al. 2001] .
Furthermore, the definition of EPCs is complicated since they seemingly are comprised of two distinct cell populations [Gulati et al. 2003a; Gehling et al. 2000; Lin et al. 2000] . Early outgrowth cells from isolated EPCs, which are used for transplantation in most studies possess the phenotype of monocytes, do not proliferate and begin to gradually die after a few weeks in culture [Fernandez Pujol et al. 2000 , Eggermann et al. 2003 , Rehman et al. 2003 , Hur et al. 2004 . In contrast, late outgrowth cells, which arise from culture colonies more than 2 weeks after isolation, proliferate very rapidly and resemble microvascular ECs with a cobblestone morphology [Delorme et al. 2005; Yoon et al. 2005; Hur et al. 2004; Gulati et al. 2003a Gulati et al. , 2003b Because of this replicative potential, these late outgrowth cells are considered to be true stem/progenitor cells. The distinction of these two cell types is confirmed by their expression of different markers. Late outgrowth cells do not express the monocyte marker CD14 and have a low expression of the pan-leukocyte marker CD45 Lin et al. 2000] . Despite the obvious in vitro distinction between early and late outgrowth cells, their in vivo or therapeutic significance remains unclear. Most early studies of cell therapy utilized early outgrowth cells and these transplanted cells were thought to replace damaged endothelium and/or contribute to neovascularization [Murayama et al. 2002; Jackson et al. 2001; Llevadot et al. 2001; Lyden et al. 2001; Crosby et al. 2000] . However, recent studies reported that early outgrowth cells might enhance neovascularization in an indirect paracine manner [Yoder et al. 2007; Yoon et al. 2005; Rehman et al. 2003 ]. In contrast, late outgrowth cells have not been well studied in vivo [Yoon et al. 2005; Hur et al. 2004; Gulati et al. 2003b] . Therefore, clarification of the character of EPCs is critical for determining the optimal cell for EPC therapy.
How does EPC enhance neovascularization?
In small animal models of hindlimb ischemia, direct injection of human circulating EPCs improved neovascularization and limb blood flow [Kalka et al. 2000] . Similarly, studies using various myocardial ischemia models have shown that systemically administered or directly injected EPCs stimulate angiogenesis, with subsequent improvement in myocardial perfusion and left ventricular function [Kawamoto et al. 2003 Kocher et al. 2001] . Although it is difficult to collectively understand the data from studies since they employ various cell types and doses, the preclinical evidence for the ability of EPCs to stimulate neovascularization seems to be obvious. Mature ECs have been shown to lack the ability to induce neovascularization [Hur et al. 2004; Kocher et al. 2001; Kalka et al. 2000] , suggesting that the undifferentiated nature of EPCs is crucial to their therapeutic function.
The mechanism by which EPCs stimulate neovascularization was initially thought to involve EPC differentiation into ECs and incorporation into neovessels. However, studies have shown that actual EPC incorporation into the vasculature is often low [Yamahara et al. 2008; Lyden et al. 2001] . Recently, their ability to stimulate neovascularization via paracrine effects has gained greater attention [Urbich et al. 2005] . This is supported by evidence for their ability to secrete various growth factors including VEGF, stromal cell-derived factor-1 (SDF-1), insulin-like growth factor-1 (IGF-1), and hepatocyte growth factor (HGF), which could stimulate angiogenesis [Lyden et al. 2001] . Therefore, the overall neovascularization induced by EPCs might be dependent not only on their ability to incorporate into the vasculature, but also on their ability to secrete factors that stimulate adjacent ECs. Although the question of how EPCs actually enhance neovascularization has not been satisfactorily answered, results from experiments have supported the use of EPCs for various therapeutic purposes, some of which have already been initiated clinically.
Cell therapy for myocardial infarction using EPCs
Preclinical experiments There are many explanations for the mechanism by which EPCs improve myocardial function in post-myocardial infarction (MI) after cell therapy. Previous studies showed that EPCs could transdifferentiate into cardiomyocytes, ECs and smooth muscle cells (SMCs) [Badorff et al. 2003; Yeh et al. 2003 ]. Now much controversy exists regarding the ability of EPCs to differentiate into cells other than ECs, but still the ability of EPCs to improve cardiac function post-MI is supported by a number of preclinical studies [Wu et al. 2006; Kawamoto et al. 2003 Kawamoto et al. , 2001 Kocher et al. 2001; Asahara et al. 1999a] . Many theories exist explaining the benefit to MI patients following EPC transplantation. First, transplanted EPCs were reported to stimulate neovascularization in the peri-infarct zone through direct endothelial incorporation or paracrine effect [Urbich et al. 2005] , rescuing ischemia and increasing myocardial perfusion [Kocher et al. 2001] . The increased perfusion would improve myocardial regional contractility, thereby increasing myocardial function. Second, transplanted EPCs may attenuate deleterious ventricular remodeling, as was suggested by several groups [Kocher et al. 2001; Orlic et al. 2001a,b] . Regenerating lost myocardial tissue would also lead to increased contractility and improved cardiac function. Recent experimental reports of cell therapy using EPCs in post-MI patients suggest that these processes occur synergistically. If the myocardial perfusion is augmented, myocyte apoptosis is prevented, and damaged cells have a better chance of surviving and regenerating lost myocardium [Kocher et al. 2001] . Also, EPCs were reported to stimulate mature ECs and cardiac resident progenitor cells via the secretion of VEGF, SDF-1 and IGF-1, which would enhance angiogenesis and myogenesis [Urbich et al. 2005] . Because elucidating such mechanisms is difficult in animals, and even more so in humans, there is little consensus for EPC-mediated myocardial regeneration post-MI.
An alternative strategy for cell therapy using EPCs is the mobilization of these cells from BM, which can avoid the need for cell isolation and delivery. Hypoxia-inducible factor 1 (HIF-1) produced in ischemic tissue stimulates secretion of VEGF and SDF-1, which can act synergistically to mobilize EPCs from BM via a matrix metalloproteinase (MMP-9) dependent mechanism [De Falco et al. 2004; Heissig et al. 2002; Takahashi et al. 1999] , VEGF [Asahara et al. 1999b] granulocyte-colony stimulating factor (G-CSF) [Ohtsuka et al. 2004; Cho et al. 2003 ], SDF-1 [De Falco et al. 2004] and erythropoietin [Bahlmann et al. 2004 [Bahlmann et al. , 2003 ] have been reported to increase EPC mobilization in preclinical models, with subsequent myocardial neovascularization and improved cardiac function after acute MI [Ohtsuka et al. 2004; Orlic et al. 2001c; Takahashi et al. 1999 ].
In addition, recent reports suggest that non-BMderived EPCs might be more important than BM-derived EPCs in the setting of postnatal neovascularization [Urayama et al. 2008; Aicher et al. 2007; Smart et al. 2007] . Aicher et al. reported that circulating progenitor cells are mobilized from organs such as liver and intestine and contribute to neovascularization following tissue ischemia. EPCs are also mobilized from tissueresident sources including epicardium in response to paracrine factors. These findings will provide the basis for a new physiological concept of EPCs and for possible therapeutic applications for ischemic disorders.
Clinical trials
Several clinical trials have been performed to test the regenerative capacity of BM or peripheral blood-derived cells for the treatment of cardiovascular diseases. Most trials using BM cells have utilized a density gradient to separate mononuclear cells consisting of a mixture of primitive hematopoietic, endothelial and mesenchymal stem/progenitor cell populations as well as mature monocytes and lymphcytes. These trials were not designed to determine the appropriate cell type for transplantation. Because we focused on the role of EPCs for regeneration of the vasculature, we only described clinical trials designed to use EPCs.
The TOPCARE-AMI clinical study was the first trial to show the efficacy of EPCs derived from peripheral blood [Assmus et al. 2002 , Schachinger et al. 2004 ]. This trial allocated 59 patients who had AMI and successful percutaneous intervention (PCI) within 6 days to receive either autologous BM-derived mononuclear cells (n ¼ 29) or peripheral blood-derived EPCs (n ¼ 30) via intracoronary catheter delivery. Improved ejection fraction, coronary flow reserve and myocardial viability in the infarct zone were observed in the cell therapy groups compared with patients receiving PCI and medical treatment. As measured by quantitative left ventricular (LV) angiography at four months, LV ejection fraction (EF) significantly increased (50 AE 10% to 58 AE 10%), and end-systolic volumes significantly decreased (54 AE 19 ml to 44 AE 20 ml). There were no significant differences between the two cell groups. Contrastenhanced magnetic resonance imaging after 1 year revealed an increased EF and reduced infarct size. Stamm et al. [2003] attempted to isolate EPCs using surface marker CD133 from BM and injected along the infarct border zone at the time of coronary artery bypass in six patients with recent MI. After surgery, all patients were alive and well, global LV function was enhanced in four patients, and infarct tissue perfusion had improved in five patients. Recently, Erbs and colleagues [2005] reported a randomized study in patients after recanalization of chronic coronary total occlusion (CTO) who received intracoronary EPCs or placebo. They mobilized BM cells using G-CSF, harvested EPCs from peripheral blood and infused EPCs via the coronary artery. After recanalization of CTO, 26 patients were randomly assigned to the treatment and control groups. At 3 months there was an increase in coronary flow reserve of 43%, and the number of hibernating segments in the target region had declined in the treatment group, whereas no significant changes were observed in the control group. MRI revealed a reduction in infarct size of 16% and an increase in LV ejection fraction of 14% in the treatment group (from 51.7 AE 3.7 to 58.9 AE 3.2%) because of an augmented wall motion in the target region. Although the precise mechanisms of functional improvement remain to be elucidated, based on the observations of these trials, regenerative therapy using EPCs appears to interfere with the development of postinfarction heart failure.
Clinical trials studying the ability of G-CSF to mobilize EPCs in patients with coronary artery disease did not reach a conclusion on efficacy. Results from recently randomized controlled trials have shown no improvement in myocardial function following G-CSF administration, despite an increase in circulating EPC levels [Zohlnhofer et al. 2007 It is reported that an inverse correlation exists between the number of coronary artery disease risk factors and the number and migratory ability of EPCs [Hill et al. 2003; Tepper et al. 2002] . Reports also suggest that advanced age [Heiss et al. 2005] , smoking [Michaud et al. 2006] , and diabetes [Loomans et al. 2004; Tepper et al. 2002] lead to impaired survival, proliferation, migration and reduced incorporation into vascular structures of EPCs. Since cell therapy using EPCs is done in an autologous manner, EPC dysfunction may reduce the therapeutic efficacy of cell therapy. Recent reports demonstrate that HMG-CoA reductase inhibitors (statins) [Dimmeler et al. 2001] , estrogens [Iwakura et al. 2003 ], exercise [Laufs et al. 2004] , and cessation of smoking [Kondo et al. 2004] enhance the number of circulating EPCs in patients, which is more practical than growth factor or chemokine administration to improve EPC function.
ES cell-derived ECs
Recent reports suggest that the number of EPCs in bone marrow or peripheral blood is limited [Kalka et al. 2000] . In addition, somatic stem/ progenitor cells usually have a limited proliferative capacity, thus expansion of sufficient EPC populations for therapeutic angiogenesis remains a major task. In contrast, ES cells have an excellent self-renewal capacity and can be expanded without limit. Therefore, ES cells could be feasible as a novel cell source for therapeutic angiogenesis. Recently, we were able to clarify the differentiation process from human ES cells to mature vascular cells (Figure 1) [Sone et al. 2007 [Sone et al. , 2003 ]. Unlike mouse ES cells, undifferentiated human ES cells already express VEGFR-2, but after differentiation, a VEGFR-2-positive but tumor rejection antigen 1-60 (TRA1-60; undifferentiated marker)-negative population emerged. These VEGF-R2-positive TRA1-60-negative cells were also positive for platelet-derived growth factor (PDGF) receptor and ß chains and could be effectively differentiated into both VE-cadherin þ ECs and SMA þ MCs. VEcadherin þ cells, which were also CD34 þ and VEGFR-2 þ were considered to be ECs in the early differentiation stage, and could be easily By culturing undifferentiated human ES cells on OP9 feeder cells, VEGFR-2 expression first disappeared and then reappeared after differentiation. After the isolation of TRA1-60-negative, VEGFR-2-positive and VE-cadherin-negative-cells by a cell sorter, additional culturing of these cells with VEGF resulted in the appearance of VE-cadherin þ ECs. In the presence of PDGF-BB, these VEGFR-2 þ VE-cadherin À cells can also differentiate into SMA þ MCs. Therefore, human ES cell-derived TRA1-60
expanded while maintaining their maturity and form a network structure on Matrigel-coated dishes.
Based upon these findings, we transplanted human ES cell-derived vascular cells in a murine hindlimb ischemia model [Yamahara et al. 2008] . After the expansion of human VPC-derived ECs and MCs, these cells were intra-arterially administered, resulting in significantly augmented blood flow in nude mice with experimentally induced ischemic hindlimb, compared with human peripheral blood or umbilical cord-derived EPCs. Transplanted human VPCderived vascular cells were incorporated into the host circulation as both ECs and MCs, whereas a considerable number of transplanted EPCs were localized inside the capillary lumen, not in the vessel wall (Figure 2) . Recently, Ferreira et al. [2007] reported that transplantation of human ES-cell-derived ECs into nude mice using Matrigel as a scaffold contributed to the formation of blood vessels. Yang et al. [2008] demonstrated that human ES-cell-derived cardiovascular progenitor cells transplanted into the heart of NOD/SCID mice could differentiate into the cardiac, endothelial and vascular smooth muscle lineages. However, they did not show the direct integration of transplanted human ES-cell-derived ECs and MCs into host blood vessels. Judging from the double staining, using intravenously injected isolectin B 4 and anti-human specific CD31 antibody we found that the transplanted human VPC-derived EC incorporated into host circulating vessels. These transplanted ECs could on their own form de novo capillaries, as reported by other groups [Cho et al. 2007 ]. In addition, by the double immunostaining of human-specific smooth muscle myosin heavy chain 1 and -smooth muscle actin (SMA), we confirmed that transplanted human VPC-derived MCs were also incorporated into host vessel walls. We demonstrated for the first time the structural contribution of transplanted human VPC-derived ECs and MCs to form new vessels in the process of vascular regeneration.
We also confirmed that the combined transplantation of human VPC-derived ECs and MCs could markedly induce vascular regeneration, compared with the single fraction transplantation of VPC-derived ECs or MCs (Figure 3) . Interaction between ECs and MCs is essential for vascular development and maintenance of vascular stability [Chan-Ling et al. 2004] . Compared with EC-or MC-transplanted mice only, the mice transplanted with the combined transplantation showed significant improvement after the induction of ischemic hindlimb. At day 42 after cell transplantation, the blood flow of ischemic hindlimb in the EC þ MC group was significantly higher compared with the EC-or MC-transplanted groups only. Mouse and/or human CD31 and also SMA positive capillary density at day 42 significantly increased in the EC þ MC group. We also found that the density of SMA-positive arterioles also significantly increased in the EC þ MC group. Therefore, combined transplantation of human VPCderived ECs and MCs could synergistically contribute to vascular regeneration.
These results indicate that human ES-cellderived ECs and MCs can be used as a new promising cell source for therapeutic vascular regeneration in patients with tissue ischemia. However, to enable their therapeutic potential to be realized, effective strategies need to be developed to produce sufficient quantities of human ES-cell-derived ECs and MCs. In addition, because human ES cell-derived differentiated cells will express transplant antigens including human leukocyte antigens (HLAs), effective prevention of graft rejection is also needed. Recently, Taylor et al. [2005] proposed the creation of a bank of HLA-typed human ES cells from which a best match could be selected, helping to reduce the likelihood of graft rejection [Nakajima et al. 2007; Taylor et al. 2005] . However, use of human embryos faces ethical controversies that hinder the application of human ES cells. One way to circumvent this issue is to induce pluripotent status in somatic cells by direct reprogramming. Takahashi et al. [2007] demonstrated the generation of induced pluripotent stem (iPS) cells from human dermal fibroblasts by transduction of four defined transcription factors: Oct3/4, Sox2, Klf4, and c-Myc. In theory, reprogramming a patient's somatic cells into pluripotent stem cells can facilitate differentiation into the required cell type for retransplantation therapy. Once the safety issue is overcome, human iPS cells should be applicable in regenerative medicine.
Conclusion
Although cell therapy using EPCs is now being performed clinically for cardiac disease, the mechanism by which EPCs enhance endothelial repair and neovascularization has not been determined. In addition, because of the limited proliferative capacity of EPCs, human ES-cell-derived ECs could potentially be useful as an alternative cell source for vascular regenerative therapy. However, human ES cell-derived vascular cell therapy should be further tested in preclinical trials to confirm its therapeutic effect in the treatment of ischemic diseases. Figure 3 . Augmented vascular regeneration by intra-arterial transplantation of human VPC-derived vascular cells in a murine hindlimb ischemia model. Serial laser Doppler perfusion image analysis of hindlimb ischemia in the transplanted mice. At day 14, the blood flow of the ischemic limb in all cell transplanted groups increased significantly compared to the control group (white arrowhead). After 42 days, significant blood flow recovery was observed in and human VPC-derived EC and/or MC-transplanted groups (white arrow), but not in EPC.
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